You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR ZAROXOLYN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ZAROXOLYN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00649051 ↗ Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg Completed Mylan Pharmaceuticals Phase 1 2002-12-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg) dose administration under fasting conditions.
NCT00649181 ↗ Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg Completed Mylan Pharmaceuticals Phase 1 2003-10-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose administration under fasting conditions.
NCT00650195 ↗ Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg Completed Mylan Pharmaceuticals Phase 1 2004-02-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose administration under fasting conditions.
NCT00904488 ↗ Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Terminated University of Illinois at Chicago Phase 4 2008-10-01 The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ZAROXOLYN

Condition Name

Condition Name for ZAROXOLYN
Intervention Trials
Healthy 3
Heart Failure 2
Heart Failure Acute 2
Heart Failure With Reduced Ejection Fraction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ZAROXOLYN
Intervention Trials
Heart Failure 4
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ZAROXOLYN

Trials by Country

Trials by Country for ZAROXOLYN
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ZAROXOLYN
Location Trials
West Virginia 2
Maryland 1
Virginia 1
Tennessee 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ZAROXOLYN

Clinical Trial Phase

Clinical Trial Phase for ZAROXOLYN
Clinical Trial Phase Trials
Phase 4 4
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ZAROXOLYN
Clinical Trial Phase Trials
Completed 4
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ZAROXOLYN

Sponsor Name

Sponsor Name for ZAROXOLYN
Sponsor Trials
Mylan Pharmaceuticals 3
University of Illinois at Chicago 1
Virginia Commonwealth University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ZAROXOLYN
Sponsor Trials
Other 7
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.